Tags

Type your tag names separated by a space and hit enter

Recent advances in rhinovirus therapeutics.
Curr Drug Targets Infect Disord. 2004 Dec; 4(4):331-7.CD

Abstract

Human rhinoviruses are the major causative agents of the common cold. Because there are greater than 100 viral serotypes, little immunological protection is afforded to humans by prior rhinovirus exposure, which accounts for the high incidence of infection. In most cases, rhinovirus leads to a short self-limiting illness. However, for asthmatics, the elderly and immunocompromised patients, rhinovirus infection can lead to life-threatening complications. This has spurred a consistent effort over recent decades to identify effective treatments and preventions for rhinovirus infection. While some work has focused on alleviating the symptoms induced as a result of inflammatory pathways stimulated by rhinoviruses, the majority of the research has been focused on limiting or preventing viral infection altogether. Various approaches have been taken to halt rhinovirus infection. Prevention of virus-cell interaction has been the aim of research on viral capsid binders and cell receptor blockers. Interference with correct viral protein processing is the goal of the design and testing of protease inhibitors. Current work is attempting to interfere with viral RNA replication by testing silencing RNA molecules. In this review, we will discuss recent advances in the development and testing of human rhinovirus therapeutics.

Authors+Show Affiliations

Perlan Therapeutics Inc., 6310 Nancy Ridge Drive, Suite 102, San Diego, CA 92121, USA. ccharles@perlan.com.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

15578974

Citation

Charles, Catherine H., et al. "Recent Advances in Rhinovirus Therapeutics." Current Drug Targets. Infectious Disorders, vol. 4, no. 4, 2004, pp. 331-7.
Charles CH, Yelmene M, Luo GX. Recent advances in rhinovirus therapeutics. Curr Drug Targets Infect Disord. 2004;4(4):331-7.
Charles, C. H., Yelmene, M., & Luo, G. X. (2004). Recent advances in rhinovirus therapeutics. Current Drug Targets. Infectious Disorders, 4(4), 331-7.
Charles CH, Yelmene M, Luo GX. Recent Advances in Rhinovirus Therapeutics. Curr Drug Targets Infect Disord. 2004;4(4):331-7. PubMed PMID: 15578974.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Recent advances in rhinovirus therapeutics. AU - Charles,Catherine H, AU - Yelmene,Michele, AU - Luo,Guang X, PY - 2004/12/8/pubmed PY - 2005/4/1/medline PY - 2004/12/8/entrez SP - 331 EP - 7 JF - Current drug targets. Infectious disorders JO - Curr Drug Targets Infect Disord VL - 4 IS - 4 N2 - Human rhinoviruses are the major causative agents of the common cold. Because there are greater than 100 viral serotypes, little immunological protection is afforded to humans by prior rhinovirus exposure, which accounts for the high incidence of infection. In most cases, rhinovirus leads to a short self-limiting illness. However, for asthmatics, the elderly and immunocompromised patients, rhinovirus infection can lead to life-threatening complications. This has spurred a consistent effort over recent decades to identify effective treatments and preventions for rhinovirus infection. While some work has focused on alleviating the symptoms induced as a result of inflammatory pathways stimulated by rhinoviruses, the majority of the research has been focused on limiting or preventing viral infection altogether. Various approaches have been taken to halt rhinovirus infection. Prevention of virus-cell interaction has been the aim of research on viral capsid binders and cell receptor blockers. Interference with correct viral protein processing is the goal of the design and testing of protease inhibitors. Current work is attempting to interfere with viral RNA replication by testing silencing RNA molecules. In this review, we will discuss recent advances in the development and testing of human rhinovirus therapeutics. SN - 1568-0053 UR - https://www.unboundmedicine.com/medline/citation/15578974/Recent_advances_in_rhinovirus_therapeutics_ L2 - https://www.ingentaconnect.com/openurl?genre=article&issn=1568-0053&volume=4&issue=4&spage=331&aulast=Charles DB - PRIME DP - Unbound Medicine ER -